

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
April 23, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 22, 2014

Progenics Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Delaware                              000-23143      13-3379479  
(State or other jurisdiction      (Commission      (IRS Employer  
of incorporation)                      File Number)      Identification No.)

777 Old Saw Mill River Road,                              10591  
Tarrytown, New York  
(Address of principal executive offices)      (Zip Code)  
Registrant's telephone number, including area code (914)  
789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On April 22, 2014, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) announced that the European Medicines Agency has accepted for review Salix's submission for a variation of the existing Marketing Authorization for RELISTOR<sup>®</sup> subcutaneous injection to include the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

A copy of the joint release is included in this Report as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press Release dated April 22, 2014.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ANGELO W. LOVALLO, JR.

Angelo W. Lovallo, Jr.

Vice President - Finance & Treasurer

(Principal Financial and Accounting Officer)

Date: April 23, 2014